Cooper Companies Misses Q3 Revenue, Guides Q4 Growth to 0-2% on Inventory Overhang
COO is trading near its 52-week low of $58.89 (8.6% below the low) on elevated volume (3.7× avg).
Summary
Cooper Companies reported fiscal Q3 revenue of $1.07 billion, missing the $1.10 billion consensus, while adjusted EPS of $1.15 beat by $0.03. The miss was driven by a reduction in U.S. channel inventory in the CooperVision segment, which management expects to continue into Q4, guiding to flat to negative CooperVision growth and overall organic growth of 0%-2%. Q4 revenue guidance of $1.057-$1.080 billion and EPS of $1.05-$1.09 came in below Q3's pace, and shares fell about 14% in extended trading. The company also repurchased $339.1 million of stock and completed a strategic review, but the near-term inventory overhang and softer guidance overshadow these positives. Investors will watch whether the inventory destocking resolves by fiscal 2027 and whether the fertility segment's 5% organic growth can offset CooperVision weakness.
At the time of this announcement, COO was trading at $53.80 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $12.4B. The 52-week trading range was $58.89 to $89.83. This news item was assessed with negative market sentiment and an importance score of 8 out of 10. Source: Reuters.